Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093366 · ClinicalTrials.gov registry record · Phase 1
Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00093366 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 32 participants.
The verdict
NCT00093366, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies such as etanercept may interfere with the growth of the cancer cells. Combining chemotherapy with biological therapy may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects of giving arsenic trioxide together with etanercept and to see how well it works in treating patients with myelodysplastic syndromes.
Interventions
- DRUG arsenic trioxide
- BIOLOGICAL etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2004-06 |
| Est. Completion | 2006-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093366
The ClinicalTrials.gov registry entry for NCT00093366 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which arsenic trioxide is the first listed.
NCT00093366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093366 about?
NCT00093366 is a clinical study titled "Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes". RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies such as etanercept may interfere with the growth of the cancer cells. Combining chemotherapy with biological therapy may kill m...
What is the current status of trial NCT00093366?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2004-06. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00093366?
The interventions under investigation include: arsenic trioxide (DRUG), etanercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT00093366?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.